Indeed, combinatorial treatment with anti-VSIR and anti-PD-1 or PD-L1 antibodies achieved synergistic therapeutic efficacy in syngeneic murine tumor models [86,87,88,89]. The gene discussed is CD274; the disease is neoplasm.